

Prior Authorization Review Panel

Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 05/01/2021
Policy Number: PA.CP.PHAR.477	Effective Date: 08/2020 Revision Date: 04/2021
Policy Name: Risdiplam (Evrysti)	
<p>Type of Submission – <u>Check all that apply:</u></p> <p> <input type="checkbox"/> New Policy <input checked="" type="checkbox"/> Revised Policy* <input type="checkbox"/> Annual Review - No Revisions <input type="checkbox"/> Statewide PDL - <i>Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.</i> </p>	
<p>*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.</p> <p>Please provide any changes or clarifying information for the policy below:</p> <p>2Q 2021 annual review: no significant changes; references reviewed and updated.</p>	
Name of Authorized Individual (Please type or print): Auren Weinberg, MD	Signature of Authorized Individual: 

Clinical Policy: Risdiplam (Evrysdi)

Reference Number: PA.CP.PHAR.477

Effective Date: 08/2020

Last Review Date: 04/2021

[Revision Log](#)

Description

Risdiplam (Evrysdi™) is a survival motor neuron 2 (SMN2) gene pre-mRNA splicing modifier.

FDA Approved Indication(s)

Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health & Wellness® that Evrysdi is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Spinal Muscular Atrophy (must meet all):

1. Diagnosis of SMA
2. Genetic testing confirms the presence of one of the following (a, b, or c):
 - a. Homozygous deletions of SMN1 gene (e.g., absence of the SMN1 gene);
 - b. Homozygous mutation in the SMN1 gene (e.g., biallelic mutations of exon 7);
 - c. Compound heterozygous mutation in the SMN1 gene [e.g., deletion of SMN1 exon 7 (allele 1) and mutation of SMN1 (allele 2)];
3. Prescribed by or in consultation with a neurologist;
4. Age \geq 2 months;
5. Documentation of one of the following baseline scores (*see Appendix D*) (a or b):
 - a. For age $<$ 2 years: Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorder (CHOP-INTEND) score or Hammersmith Infant Neurological Examination (HINE) Section 2 motor milestone score;
 - b. For age \geq 2 years: Hammersmith functional motor scale expanded (HF MSE) score, Revised Hammersmith Scale (RHS), Upper Limb Module (ULM), Revised Upper Limb Module (RULM), or 6-Minute Walk Test (6MWT);
6. Evrysdi is not initiated simultaneously with Spinraza® and/or Zolgensma®;
7. If the member is currently on Spinraza, documentation of prescriber attestation of Spinraza discontinuation;
8. If the member has a history of treatment with Zolgensma, must meet both of the following (a and b):
 - a. Provider must submit evidence of poor response to Zolgensma (e.g., sustained decrease in CHOP-INTEND score over a period of 6 months);
 - b. Documentation of prescriber attestation of clinical deterioration;
9. Request meets one of the following (a, b, or c):

- a. If 2 months of age to less than 2 years of age, dose does not exceed 0.2 mg/kg per day;
- b. If 2 years of age and older, weighing less than 20 kg, dose does not exceed 0.25 mg/kg per day;
- c. If 2 years of age and older, weighing 20 kg or more, dose does not exceed 5 mg per day.

Approval duration: 6 months

B. Other diagnoses/indications

1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

II. Continued Therapy

A. Spinal Muscular Atrophy (must meet all):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies;
2. Evrysdi is not initiated concurrently with Spinraza and/or Zolgensma;
3. Provider submits documentation of the number of categories of improvement and decline in motor milestones based on the CHOP-INTEND, HINE, or HFMSE score (based on member's age) since the most recent approval (*see Appendix D*)
4. If request is for a dose increase, request meets one of the following (a, b, or c):
 - a. If 2 months of age to less than 2 years of age, new dose does not exceed 0.2 mg/kg per day;
 - b. If 2 years of age and older, weighing less than 20 kg, new dose does not exceed 0.25 mg/kg per day;
 - c. If 2 years of age and older, weighing 20 kg or more, new dose does not exceed 5 mg per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – PA.CP.PMN.53**

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CHOP-INTEND: Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorder
 FDA: Food and Drug Administration
 HFMSE: Hammersmith functional motor scale expanded
 HINE: Hammersmith infant neurological examination

MPLA: multiplex ligation-dependent probe amplification
 RHS: Revised Hammersmith scale
 RULM: Revised upper limb module
 SMA: spinal muscular atrophy
 SMN: survival motor neuron
 ULM: upper limb module
 6MWT: 6-minute walk test

Appendix B: Therapeutic Alternatives
 Not applicable

Appendix C: Contraindications/Boxed Warnings
 None reported

Appendix D: General Information

- SMA is an autosomal recessive genetic disorder. It is caused by mutations in the SMN1 (survival motor neuron) gene that is found on chromosome 5 (hence the name 5q-SMA). To develop SMA, an individual must inherit two faulty (deletion or mutation) SMN1 genes, one from each parent.
- SMN-related SMA is classified as type 1 through 4 depending on time of onset. The age of disease onset of symptoms correlates with disease severity: the earlier the age of onset, the greater the impact on motor function. Children who display symptoms at birth or in infancy typically have the lowest level of functioning (type 1). SMA onset in children (types 2 and 3), teens or adults (type 4) generally correlates with increasingly higher levels of motor function.
- SMN2 gene copy and SMA types
 - SMN2 gene copy numbers are variable in individuals with spinal muscular atrophy. Higher numbers typically correlate with less severe disease.
 - More than 95% of individuals with spinal muscular atrophy retain at least 1 copy of the SMN2 gene
 - About 80% of individuals with Type I spinal muscular atrophy have 1 or 2 copies of the SMN2 gene
 - About 82% of individuals with Type II spinal muscular atrophy have 3 copies of the SMN2 gene
 - About 96% of individuals with Type III spinal muscular atrophy have 3 or 4 copies of the SMN2 gene
- The CHOP-INTEND score is a validated 16-item, 64-point scale shown to be reliable and sensitive to change over time for SMA Type 1. In a prospective cohort study of SMA type I patients (n = 34), the mean rate of decline in the CHOP-INTEND score was 1.27 points/year (95% CI 0.21-2.33, p = 0.02). A CHOP-INTEND score greater than 40 is considered a clinically meaningful change.
- The HINE Section 2 motor milestone exam is an easily performed and relatively brief standardized clinical neurological examination that is optimal for infants aged between 2 and 24 months with good inter-observer reliability. This endpoint evaluates seven

different areas of motor milestone development, with a maximum score between 2-4 points for each, depending on the milestone, and a total maximum score of 26 points.

- The HFSME score combines the Hammersmith Functional Motor Scale with a 13-item expansion module for ability to distinguish motor skills among individuals who may be older or with SMA types II and III. Each item is graded from 0 to 3, with 0 signifying no response, with a total of 66 points. HFMSE has demonstrated reliability and validity in patients with SMA. An increase of greater than 2 points in total score is unlikely in untreated SMA.
- The RHS is an ordinal scale which consist of 33 items with grades of 0,1 and 2. For individuals who can achieve the task without any compensation it is given a score of 2. For those who only attempt the movement or finish it with some form of compensation is scored 1 and sore of 0 is given when patients are unable to perform any part of the item. The total maximum score is 69 points.
- The RULM is a set of 19 tasks that measure motor function in non-ambulatory SMA patients. Each task is assessed with a 3 point ordinal scale, with a total maximum score of 37 points. Meanwhile, the maximum score for ULM was 18.
- The 6MWT is a clinical outcome measure for ambulatory SMA that has been determined to be functionally meaningful and capable of capturing disease severity.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
SMA	Weight-based dose PO QD: <ul style="list-style-type: none"> • 2 months to less than 2 years of age: 0.2 mg/kg • 2 years of age and older, weighing less than 20 kg: 0.25 mg/kg • 2 years of age and older, weigh 20 kg or more: 5 mg 	5 mg/day

VI. Product Availability

For oral solution: 60 mg risdiplam as a powder for constitution to provide 0.75 mg/mL solution

VII. References

1. Evrysdi Prescribing Information. South San Francisco, CA: Genentech Inc.; August 2020. Available at: <https://www.evrysdi.com/>. Accessed February 12, 2021.
2. Baranello G, Servais L, Day JW, et al. FIREFISH Part 1: 1-Year results on motor function in infants with Type 1 SMA receiving risdiplam (RG7916). Presented at the Annual Meeting of the American Academy of Neurology in Philadelphia, PA; May 4–10, 2019. AAN Oral Presentation.
3. Mercuri E, Baranello G, Kirschner J, et al. Update from SUNFISH Part 1: Safety, tolerability and PK/PD from the dose-finding study, including exploratory efficacy data in patients with Type 2 or 3 spinal muscular atrophy (SMA) treated with risdiplam (RG7916). Presented at the Annual Meeting of the American Academy of Neurology in Philadelphia, PA; May 4–10, 2019. AAN Oral Presentation.
4. Wang CH, Finkel RS, Bertini ES, et al. Consensus Statement for Standard of Care in Spinal Muscular Atrophy. *Journal of Child Neurology*. 2007; 22:1027-1049.

5. Cobben JM, de Visser M, Scheffer H, et al. Confirmation of clinical diagnosis in requests for prenatal prediction of SMA type I. *J Neurol Neurosurg Psychiatry*. 1993; 56: 319-21.
6. Maitre NL, Chorna O, Romeo DM, and Guzzetta A. Implementation of the Hammersmith Infant Neurological Examination in a High-Risk Infant Follow-Up Program. *Pediatric Neurology*. 2016; 65:31-38.
7. Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. *Muscle and Nerve*. 2016. 54: 836-842.
8. Ramsey D, Scoto M, Mayhew A, et al. Revised Hammersmith Scale for Spinal Muscular Atrophy: A SMA Specific Clinical Outcome Assessment Tool. *PLoS ONE*. 2017; 12(2): e0172346. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0172346>
9. Darras BT, Royden Jones H Jr, Ryan MM, et al. *Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach*. 2nd ed. London, UK: Elsevier; 2015.

Reviews, Revisions, and Approvals	Date
Policy created	08/2020
2Q 2021 annual review: no significant changes; references reviewed and updated.	04/2021